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Abstract: The development of a multimodal optical imaging system is presented that integrates
endogenous fluorescence and diffuse reflectance spectroscopy with single-wavelength spatial
frequency domain imaging (SFDI) and surface profilometry. The system images specimens at
visible wavelengths with a spatial resolution of 70 µm, a field of view of 25 cm2 and a depth of
field of ∼1.5 cm. The results of phantom experiments are presented demonstrating the system
retrieves absorption and reduced scattering coefficient maps using SFDI with <6% reconstruction
errors. A phase-shifting profilometry technique is implemented and the resulting 3-D surface
used to compute a geometric correction ensuring optical properties reconstruction errors are
maintained to <6% in curved media with height variations <20 mm. Combining SFDI-computed
optical properties with data from diffuse reflectance spectra is shown to correct fluorescence
using a model based on light transport in tissue theory. The system is used to image a human
prostate, demonstrating its ability to distinguish prostatic tissue (anterior stroma, hyperplasia,
peripheral zone) from extra-prostatic tissue (urethra, ejaculatory ducts, peri-prostatic tissue).
These techniques could be integrated in robotic-assisted surgical systems to enhance information
provided to surgeons and improve procedural accuracy by minimizing the risk of damage to
extra-prostatic tissue during radical prostatectomy procedures and eventually detect residual
cancer.
© 2020 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
1. Introduction
Prostate cancer is the most common cancer in American men, and it is associated with increasing
incidence rates [1–3]. Current prostate cancer clinical management guidelines are leading to
an increasing number of instances where patients are submitted to active surveillance (low
risk prostate cancer patients) and do not need to undergo surgery. However, surgery can be
recommended for higher risk prostate cancers and in that case the only curative treatment is
radical prostatectomy. There were more than 1300 radical prostatectomy procedures per million
men in 2011 in the United States [4–7]. Worldwide, increasing numbers of radical prostatectomy
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procedures are performed using robotic-assisted surgical systems, which can result in reduced
side effects, increased normal tissue sparing, reduced loss of blood and shorter hospital stays
[8,9].
Rates of remission following radical prostatectomy procedures are strongly influenced by the
extent to which completeness of cancer resection is attained [10,11]. Because cancer frequently
extends beyond the prostatic capsule [12], ensuring safety margins is often the adopted surgical
strategy. The extent of surgical resection is then determined by multiple factors, including patient
pre-surgical prostate-specific antigen (PSA) levels, clinical stage and pathological findings at
diagnosis, as well as quality-of-life after the surgery [13–15]. Procedures are not only optimal
when residual extra-prostatic cancer is avoided but also when damage to critical organs and
structures, including bladder and nerves [16], is minimized. Less extended margins lower the
risk of damage to surrounding tissue and increase post-procedure patient satisfaction by reducing
side effects [17,18]. However, positive margins from un-resected cancer extending beyond the
prostate decrease survival rates and lead to additional treatments [19,20]. As a result, radical
prostatectomy procedures are performed by balancing the need to remove the entire prostate and
leave no residual tumor tissue against the need to minimize healthy tissue damage.
Unlike surgical oncology approaches where co-registration methods with other imaging
modalities are used to guide resection (e.g. magnetic resonance imaging (MRI) in brain cancer)
[21], prostate cancer is usually not detectable using standard imaging techniques although
MRI-based prostate cancer detection shows promises [22]. Surgeons thus typically rely on low
accuracy methods, including prostate-specific antigen (PSA) testing and transrectal ultrasound
(TRUS)-guided biopsies, to plan the procedure and determine target margin sizes pre-operatively
[23]. As a result of the limitations of current prostate cancer diagnostic approaches, there
is a need for new methods to enhance intraoperative tissue information through in situ tissue
characterization.
Up until now, point probes were used to characterize prostate tissue using optical coherence
tomography (OCT) [24], Raman spectroscopy [25], diffuse reflectance spectroscopy [26] as
well as exogenous fluorescence from aminolevulinic acid-induced (ALA) protoporphyrin IX
(PpIX) [27] and endogenous fluorescence [28]. All these approaches provided tissue imaging
fields of view at mesoscopic scales i.e. of the order of one millimeter. Endogenous fluorescence
results from tissue-native fluorescent molecules, thus giving access to molecular information
without the need to inject a molecular tracer [29]. Although most intrinsic tissue fluorophore
excitation bands are in the ultraviolet (UV), multiple molecules can still be detected through
excitation above the UVA region (>380 nm) into the violet-blue part of the visible spectrum.
Those include nicotinamide adenine dinucleotide (NADH) and flavins that can be used as a
surrogate for cellular metabolism-associated mitochondrial activity [30,31]. Other fluorophores
that can be excited with visible light include the structural proteins elastin and collagen as well as
porphyrins, which were shown to accumulate specifically in some cancers [32]. Intrinsic tissue
fluorescence detection has been achieved for multiple tissue types and pathologies [33], including
for the detection of cancer in prostate and breast [34]. Although most work in mesoscopic
intrinsic tissue fluorescence characterization was done with point probes, technologies were
developed for macroscopic wide-field imaging in a limited number of oncology studies [35,36].
A practical limitation when attempting to detect intrinsic tissue fluorescence is the small
quantum yields of fluorophores when compared to the cross-sections associated with absorption
from tissue chromophores (e.g. hemoglobin and pigment molecules such as melanin) and
elastic scattering from cell nuclei, membranes and organelles. These competing light interaction
mechanisms affect the fluorescence signal, which is non-quantitative in the sense that tissue regions
with a homogeneous concentration of fluorophores but with heterogeneous absorption/scattering
properties could show different levels of detected fluorescence [37]. As a result, several
mathematical models based on light transport in turbid media were developed for point-probe
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measurements to decouple absorption and scattering from fluorescence by applying an attenuation
correction [38–40]. The objective in this line of research is to derive measures that are linearly
related to the concentration of a fluorophore. This has been achieved for in situ brain tissue
characterization when detecting ALA-induced PpIX with point-probes and wide-field imaging
systems [41,42]. This work led to PpIX tissue concentration values CPpIX decoupled from the
effect of absorption and scattering. Applying the same methods to obtain in situ concentration
values of intrinsic tissue fluorophores was attempted only in a limited number of studies but
provided additional challenges because of the multiplicity of fluorescent markers contributing
to the signal [43]. In fact, quantifying the concentration of each individual fluorescent marker
would require the use of spectral de-convolution techniques but this has not been attempted yet
for in situ endogenous macroscopic fluorescence detection.
Point-probe measurements typically offer fields of view of the order of 1 mm2, which for
some surgical applications can be insufficient for clinical adoption [44]. Thus, research groups
have developed macroscopic attenuation-corrected fluorescence imaging techniques based on
diffuse reflectance measurements [45]. In particular, the advent of spatial frequency domain
imaging (SFDI) allowed the quantification of absorption/scattering properties across wide-field
images which led to the development of light transport-based attenuation corrections adapted
to wide-field imaging geometries [46–48]. This technique is called attenuation-corrected
fluorescence (CF) imaging [49]. Such systems have been applied to PpIX quantification for skin
cancer characterization [50,51], surgical guidance in neurosurgery [52,53] and photodynamic
therapy (PDT) drug concentration monitoring [54]. Real-time CF imaging has also been attained
in tissue phantoms [55].
Here we are presenting the development, detailed tissue phantoms characterization and prelim-
inary in-human validation of a wide-field spectroscopic imaging system detecting reflectance
spectra in the visible range as well as endogenous fluorescence from violet light excitation. The
system also integrates SFDI to compute absorption/scattering coefficient maps and perform 3-D
surface profiling. This information, along with reflectance and fluorescence spectra, is used in
the scope of a light transport-based attenuation-corrected fluorescence (CF) model to compute
a measure that can be used as a surrogate for the concentration of intrinsic tissue fluorescent
molecules. The calibration and development process of the system leading to SFDI-reconstructed
absorption and reduced scattering coefficients is presented with measurements in both low and
high absorption Intralipid®-based optical phantoms. Measurements in solid phantoms are used
to implement a profilometry correction accounting for sample geometry and the attenuation
correction to fluorescence measurements is tested using liquid phantoms. Multimodal images
are acquired in a human prostate following a radical prostatectomy procedure. Although cancer
detection is not considered in the proof-of-principle study, basic statistical analyses applied to
those images are presented providing preliminary evidence that biologically distinct prostate
regions can be distinguished based on fluorescence, absorption and elastic scattering tissue
optical properties. This work paves the way for a clinical study investigating the potential of the
system in surgical guidance through residual cancer detection and normal tissue sparing during
radical prostatectomy procedures.
2. Materials and methods
2.1. Multimodal imaging system
2.1.1. System hardware
The multimodal wide-field system was composed of a central detection branch surrounded by
two distinct illumination branches, one for fluorescence & reflectance spectroscopy and one for
single-wavelength SFDI (Fig. 1). Light detection was achieved using an sCMOS camera with a
4/3’’ array composed of 2048× 2048 pixels, each of dimensions 6.5× 6.5 µm (C11440-22CU,
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Hamamatsu, Japan). The camera was connected through a relay lens to a liquid crystal tunable
filter (LCTF) with operation range between 400 and 720 nm (VIS model, Varispec, USA) and a
manually adjustable linear polarizer was introduced in the detection path to control tissue specular
reflection. An aspherical objective (LM25XC, Kowa, USA) was used as the main interface for
image acquisition.
Fig. 1. (a) Photograph of the multimodal imaging system. (b) System schematics
highlighting coupling optics and the two imaging branches allowing diffuse reflectance
& fluorescence spectroscopy, single-wavelength SFDI and profilometry. (c) Flowchart
representing the data acquisition and processing workflow.
Both illumination branches used the same light source consisting of seven high-power light
emitting diodes (LED) centered at 405, 435, 475, 515, 550, 570 and 630 nm (79–536 mW,
Spectra X model, Lumencor, USA) outputted through a 3 mm-diameter liquid light guide. The
LEDs had overlapping spectra and could be powered simultaneously to emulate white light for
diffuse reflectance spectroscopic imaging. Fluorescence spectroscopy was achieved using the
405 nm source and SFDI/profilometry using the 435 nm source. The 405 nm LED was used
for fluorescence excitation since it overlapped with the extinction coefficient spectra of multiple
endogenous fluorophores including NADH, flavins, porphyrins and elastin [56]. The liquid
light guide output was collimated to ensure direct projection onto the sample. For reflectance
& fluorescence, the source was connected to a two-slot optical rail allowing rapid switching
between: i) a linear polarizer with optical axis manually adjusted to be at approximately 90° with
respect to the linear polarizer in the detection branch, or ii) two successive 390 ± 40 nm OD
> 6 bandpass filters (BrightLine FF01-390/40-25, Semrock, USA) used to cut off fluorescence
excitation from the measurements. For SFDI, a light engine (CEL5500 model, DLI, USA) with a
digital light processing chipset (DLP5500 model, Texas Instruments, USA) was used for spatial
light modulation. The light engine casing was mechanically re-engineered to accommodate extra
lenses, ensuring optical coupling with the liquid light guide. An adjustable linear polarizer was
added to the light path providing an extra degree of freedom to limit signal contributions from
specular reflections.
2.1.2. Acquisition control
Data acquisition was done using a custom LabVIEW program (National Instruments, USA)
controlling the camera and LCTF parameters (number of spectral bands, spectral range, imaging
time) for reflectance & fluorescence detection and pattern projection for SFDI measurements
(spatial frequency and phase of sine waves). The software implemented an auto-exposure
algorithm to adjust imaging time at each wavelength in order to maximize the signal-to-noise
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ratio (SNR). Reflectance & fluorescence spectroscopy measurements were acquired with the
LCTF scanning from 420 to 650 nm with steps of 5 nm while SFDI data was acquired at a fixed
LCTF wavelength centered at 435 nm.
2.2. System characterization and data processing
2.2.1. Imaging specifications
The spatial resolution of the system was determined by imaging a standard 1951 USAF resolution
target and defined by the smallest element with distinct contrast. The depth of field was also
determined using the resolution target, this time by varying the height of a z-axis stage on
which the target was deposited to determine the range for which imaging can be achieved at a
pre-specified spatial resolution associated with a 25% decrease when compared to the resolution
evaluated at the focal plane. Because it was computed based on measurements in a non-diffusive
material, the spatial resolution determined with the target must be considered a higher bound and
its actual value in tissue is expected to degrade because of diffusion from elastic scattering.
2.2.2. SFDI data calibration and geometric optical properties correction
Spatial frequency domain imaging relies on projecting sine wave patterns at multiple spatial
frequencies (kx) and phases to extract the tissue modulation transfer function Mac(kx) [57].
Because this transfer function is a function of tissue optical properties (absorption coefficient,
µa, reduced scattering coefficient, µs ′), tissue response can be measured at multiple frequencies
to recover wide-field absorption and scattering images [58]. To account for the instrument
response function, the technique requires the measured transfer function to be normalized against
a reference measurement made on a sample with known tissue optical properties [59]. An
intralipid®-based liquid phantom was used to compute the reference matrix function and white
Monte Carlo simulations (Virtual photonics technology initiative, USA) used to create a lookup
table for a large range of µa/µs couples under the hypothesis that the imaged geometry was a flat
semi-infinite slab.
A correction algorithm was implemented to account for local sample height and curvature
(i.e. angle associated with surface normal vectors), which can induce errors in reconstructed
optical properties [60]. The profile-based correction method consists of normalizing the tissue
transfer function using measured reference transfer functions for a range of distances consistent
with expected height variations when imaging specimens [61]. Briefly, by measuring a reference
transfer function at various heights and the corresponding phase, a relationship was found between
phase variation the transfer function, which allowed to compute a correction factor for every
imaged pixel. Angle correction was implemented by multiplying the reference matrix function
with the cosine of the angle formed by the normal surface vector and the camera detection
axis. The technique used four different phases since this was found to minimize artefacts in
reconstructed 3-D profiles [62].
2.2.3. Fluorescence and reflectance data calibration
Figure 2 shows the calibration/normalization procedure applied to reflectance & fluorescence
spectroscopy measurements to account for the instrument response function and produce
attenuation-corrected fluorescence (CF) images. It included: i) a shading correction based on
a reflectance standard (Spectralon, SRM-99, Labsphere, USA) measurement to compensate
for inhomogeneities in the illumination field, and ii) a normalization with a spectral irradiance
standard (63355, Newport, USA) to account for variations in system transmission across the
spectral imaging domain. The shading correction for reflectance consists of a division by
the normalized hyperspectral reflectance standard measurement. For fluorescence, the images
were divided by a normalized intensity map of the standard’s reflectance at 405 nm. Spectral
response variations were accounted for by dividing all sample measurements by a correction
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curve corresponding to a hyperspectral measurement on the spectral irradiance standard divided
by its theoretical spectrum.
Fig. 2. Data processing flowchart for reflectance & fluorescence spectroscopy imaging.
Also shown are representative images of a shading correction applied to a layer of fluorescent
beads (excitation wavelength: 405 nm, emission wavelength: 505 nm, bead diameters:
255-500 µm, Cospheric, USA) as well as a representative relative intensity spectral correction
associated with the instrument response.
2.2.4. Attenuation-corrected fluorescence
As the final processing step, a tissue light transport-based correction factor was computed and
applied to the fluorescence images. The objective was to produce images in which the dependence
of the measured fluorescence signals on elastic scattering and absorption from chromophores was
reduced. The fluorescence attenuation correction at every point in the image was implemented
using the SFDI-derived optical properties values and the spectroscopic reflectance measurement.
The model developed by Kim et al. [63] for point probe measurements was used, which consists










where the experimental measurements are the fluorescence spectrum Fraw(λ) and the reflectance
spectrum R(λ). The reflectance modeled by diffusion theory at the excitation wavelength, Rt,x, is
a function of the internal reflection parameter κ and the reduced albedo a’. These coefficients
depend on the refractive index of the sample (n  1.33 for biological tissue [64]) as well as the
absorption (µa) and reduced scattering (µs ′) coefficients at the excitation wavelength measured
using SFDI.
In Eq. (1), the effect of absorption and scattering at the emission wavelength was approximated
with a reflectance measurement R(λ). This required that two conditions be satisfied: 1) the tissue
absorption coefficient at excitation is significantly higher than its value at the emission wavelength,
and 2) the fluorophore absorption at the excitation wavelength is negligible compared to tissue
absorption from chromophores. Important absorbers in the prostate can be hemoglobin and the
molecular constituents of seminal fluid [65]. However, for ex vivomeasurements it is expected that
seminal fluid could be the main absorber since blood concentration is much lower than under in
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vivo conditions. Both hemoglobin and seminal fluid have absorption peaks near the fluorescence
excitation wavelength at 405 nm, with significantly lower values at higher wavelengths in the
visible [66,67]. Moreover, although the extinction coefficients for intrinsic tissue fluorophores
excited at 405 nm can be important, their absorption is usually orders of magnitude smaller when
compared to tissue chromophores [33,42,51]. As a result, both conditions for validity of the CF
model in Eq. (1) are expected to be satisfied in the prostate when measuring intrinsic tissue
fluorescence.
Implementing Eq. (1) requires absorption & scattering properties at the fluorescence excitation
wavelength (405 nm). However, the light transmission of both the LCTF and the digital light
projector are low at that wavelength leading to poor SNR measurements. As a result, SFDI
measurements were conducted instead at 435 nm where the transmission is ∼3 times larger. This
approximation is justified by the fact chromophore absorption coefficients peaked in the 400-435
nm region, which means absorption values at 405 and 435 nm will both be significantly higher
than those at the emission wavelengths [66,67]. Consequently, although there may be a change in
SFDI-derived optical properties between the two wavelengths it should not impact the validity of
the correction.
2.3. SFDI and profilometry measurements
2.3.1. Low absorption tissue phantoms
Liquid optical phantoms made with water, Intralipid® (Sigma-Aldrich, USA) and food coloring
dyes (McCormick, USA) were made to test the SFDI reconstruction capabilities. Theoretical
values of the reduced scattering coefficient were obtained from the literature [68,69] while the
absorption coefficient was measured using a custom single-point fibre optics spectrophotometer.
A reference set of 72 optical phantoms was made with optical properties (at 435 nm) ranging
from µa = 0.022 mm−1 to 0.44 mm−1 and µs ′ = 0.72 mm−1 to 2.16 mm−1. The µs ′/µa ratio in
this phantom set ranged from 1.6 to 98.1, in most cases satisfying the diffusion approximation
[70]. SFDI measurements were made for each phantom at 6 spatial frequencies (kx = 0.041,
0.082, 0.123, 0.144, 0.164, and 0.246 mm−1), each at 4 different phases (∆ϕ= 0°, 90°, 180°,
270°). The average power of the source over the imaging field of view was ∼0.045 mW/cm2.
Reference phantoms with different optical properties were used to reconstruct optical properties
maps for all phantoms and the average reconstructed properties across the imaging field were
compared to the theoretical values to quantify reconstruction accuracy. Error bars were computed
corresponding to the standard deviation of recovered optical properties across the imaging field.
Only results associated with the reference phantom minimizing overall reconstruction errors
were reported. Selection of the number of spatial frequencies and their specific values were
pre-determined based on measurements in optical phantoms using 15 frequencies. Tests were
performed evaluating different frequency subsets to determine combinations that minimized
mean absorption and reduced scattering coefficients reconstruction errors.
2.3.2. High absorption tissue phantoms
The optical properties of the prostate are not expected to satisfy the diffusion approximation
[71–73] since, e.g. the excitation source at 435 nm overlaps high hemoglobin absorption bands
[67]. To validate SFDI in conditions closer to what is expected in prostate specimens, a second
liquid phantom experiment was conducted in 8 phantoms with absorption ranging from µa = 0.22
mm−1 to 1.32 mm−1 and reduced scattering ranging from µs ′ = 0.72 mm−1 to 1.92 mm−1. The
µs ′/µa ratio in those phantoms ranged from 3.0 to 1.0. SFDI measurements were made following
the same protocol as for the low absorption phantoms. The data was processed using the same
model and accuracy quantified using the same metrics. The results were used to guide the
selection of an SFDI reference phantom maximizing µa and µs ′ reconstruction accuracy within
an optical properties range representative of the prostate sample (high absorption).
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2.3.3. Profilometry measurements
An experiment using a solid phantom with homogeneous optical properties was devised to
evaluate the profilometry technique by quantifying the impact of the geometric correction when
applied to compute the optical properties of irregular surfaces. Using a PDMS base, the optical
properties were varied using TiO2 for scattering and nigrosin for absorption [74]. The solution
was mixed and cast into three different mold shapes: a flat surface, a staircase with 8 steps of
equal heights (total height: 24 mm) and a quarter of a sphere with a 2 cm radius. Four phantoms
were fabricated: a flat surface with (µa, µs ′)= (0.06 mm−1, 1.3 mm−1), two staircases with (µa,
µs ′)= (0.02 mm−1, 0.88 mm−1) and (µa, µs ′)= (0.026 mm−1, 0.62 mm−1), and a sphere quadrant
with (µa, µs ′)= (0.025 mm−1, 0.9 mm−1) at 435 nm. Profilometry measurements were made at
435 nm with 4 phases (∆ϕ= 0°, 90°, 180°, 270°) at 8 spatial frequencies (kx = 0.0041, 0.0165,
0.041, 0.082, 0.123, 0.144, 0.164, 0.246 mm−1). The (µa, µs ′)= (0.026 mm−1, 0.62 mm−1)
staircase phantom was imaged and reconstructed using the (µa, µs ′)= (0.02 mm−1, 0.88 mm−1)
staircase phantom as reference. These measurements were used to characterize the performance
of the height correction algorithm. The recovered optical properties values were averaged for
each step of the staircase and the standard deviation computed to be reported as error bars. The
maps of optical properties before and after applying the geometric correction were compared by
computing the average optical properties reconstruction error for all steps of the staircase. The
sphere quadrant was imaged and reconstructed with the flat surface as a reference to characterize
the performance of the angle correction algorithm. An azimuthal angle θ was defined representing
the angular difference between the surface normal vector and the detection axis of the camera.
Regions of interest were defined corresponding to sections with ∆θ = 5° intervals ranging from
θ = 0 to 50°. The same analysis that was applied to the staircase phantoms was applied to the
quarter sphere section to evaluate the performance of the height and correction algorithms.
2.4. Fluorescence and reflectance spectroscopy tissue phantoms
Liquid phantoms were made to evaluate the CF technique using the fluorophore PpIX, which was
chosen because it had an excitation band at 405 nm. For fluorescence, light fluence was ∼4.5
mW/cm2 while for reflectance, the sum of all LEDs amounted to ∼15 mW/cm2. In total, 9 optical
phantoms were made with fluorophore concentrations 1.25, 2.5, 5 µg/ml, absorption coefficients
µa = 0.05, 0.15, 0.25 mm−1 and reduced scattering µs ′ = 0.75, 1.15, 1.5 mm−1. These phantoms
were fabricated ensuring they satisfy the assumptions of the model in Eq. (1). Both reflectance
and fluorescence measurements were made from 420 to 650 nm with steps of 5 nm (47 bands in
total). SFDI measurements were made at 435 nm (∼0.045 mW/cm2) with 8 spatial frequencies
(kx = 0.0041, 0.0165, 0.041, 0.082, 0.123, 0.144, 0.164, 0.246 mm−1) and 4 phases. To apply
an attenuation correction to the fluorescence measurements, Eq. (1) was applied at each pixel
and for each wavelength individually. The fluorescence (Fraw) and CF intensities of the 635 nm
PpIX emission peak were averaged over the whole image and the standard deviation computed
to be reported as an error bar. The performance of the attenuation correction technique was
characterized by quantitatively evaluating the correlation factor R2 between the real fluorophore
concentration and either the raw fluorescence or the CF values [75].
2.5. Ex vivo human prostate imaging
A prostate specimen was imaged from a patient that underwent radical prostatectomy at the
Centre Hospitalier de l’Université de Montréal (CHUM) and gave informed consent to participate
in the institution’s prostate cancer repository. Inclusion criteria were that preliminary biopsy
results produced more than 2 positive cores with >10% of the core being cancerous and that
excised prostates weighted more than 35 g. Following surgery, the whole organ was sent to the
pathology ward where it was weighed, inked and identified according to institutional standards.
A 10 mm thick slice was cut, placed between 2 cardboard sheets and immersed in 0.9% NaCl
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(4°C) prior to being transported to the optical imaging laboratory at the CHUM research center
where the multimodal optical imaging system was located. Inspection of the slice allowed to
determine it had surface height variations <4 mm and surface normal vectors with θ ≤ ±25°
except locally in the central prostate region (urethra) where θ > 50°. Except for the urethra,
these values are within the 24 mm height variations and 50° normal angle variations tested with
the profilometry technique. A photograph of the prostate was taken followed by multimodal
optical measurements with the system in <30 min. The specimen was then reintegrated into
the standard pathology workflow. Inspection of the stained slices by a pathologist led to the
identification of the following biologically distinct prostate regions: 1) anterior stroma, 2) urethra,
3) hyperplasia, 4) ejaculatory ducts, 5) peri-prostatic, 6) peripheral zone. The regions were then
spatially registered with the spectroscopic/SFDI measurements as shown in Fig. 7.
Optical imaging was done using the same illumination/acquisition parameters and processing
methods as for the phantom experiments in Section 2.4. To simplify data presentation and
analysis, the reflectance, fluorescence and CF spectra were dimensionally reduced by computing
the sum over all wavelengths at each image point. Imaging time was 4 s per band for reflectance
and 5 s per band for fluorescence, totalling 188 s and 235 s, respectively. Due to high prostate
absorption and limited illumination power (>2 orders of magnitude smaller than levels allowed
for skin according to ANSI laser safety standards), 10 s exposure time was required for each
SFDI spatial frequency and phase for a total of 320 s.
Reconstruction of absorption/scattering coefficients with SFDI was done using a transfer
function computed based on measurements from the high absorption reference phantom. Optical
properties (µa, µs ′ and CF) were averaged over each of the 6 prostate regions and univariate
statistical analyses performed to test whether optically derived properties could be used to
discriminate between regions. Specifically, a Kruskal-Wallis test was performed for each source
of optical contrast between all prostate regions and boxplots were produced showing median (2nd
quartile, Q2), 1st quartile (Q1), 3rd quartile (Q3), interquartile range (IQR), minimum value (Q1 -
1.5× IQR), maximum value (Q3+ 1.5× IQR) and outliers. Regions 1,3 and 6 were then grouped
as prostatic tissue and regions 2,4 and 5 as extra-prostatic tissue. Boxplots were produced for
these subgroups and a Kruskal-Wallis test performed to test the hypothesis that the two tissue
categories could be distinguished.
3. Results
3.1. Characterization of the imaging system
Based on measurements from the resolution target, the system had a spatial resolution of 70 µm,
a field of view of 5.5× 5.5 cm and a depth of field of 1.5 cm. Although they were determined
for non-diffusive media, these technical specifications are consistent with macroscopic whole
prostate tissue interrogation at mesoscopic scales as well as with expected height variations when
imaging prostate specimens.
3.2. SFDI and profilometry
3.2.1. Low absorption tissue phantoms
For each phantom, the SFDI-recovered optical properties (µa, µs ′) were averaged over the imaging
field of view and the standard deviation computed. The reference phantom used for image
reconstruction had µa = 0.05 mm−1 and µs ′ = 1.2 mm−1. The average error (across all phantoms)
from the theoretical values was 5.2% for absorption and 3.9% for scattering. Figure 3(a, b) shows
the reconstructed optical properties for each phantom against the theoretical optical properties
of the phantoms. The average standard deviation across the imaging field of view was 7.2%
for µa and 3.6% for µs ′. When restricting the optical properties to µa ≤ 0.11 mm−1, average
errors were 5.1% for µa and 3.2% for µs ′. The average error on the excluded phantoms (0.17
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mm−1 ≤ µa ≤ 0.44 mm−1) was 5.6% for µa and 5.5% for µs ′. However, when using a reference
phantom of 0.3 mm−1 absorption and 1 mm−1 reduced scattering on data from high absorption
phantoms (µa > 0.11 mm−1), average errors of 4.3% and 3.9% were obtained for µa and µs ′,
respectively.
Fig. 3. Measured vs. theoretical optical properties: (a) absorption and (b) reduced
scattering coefficients in the low absorption regime, (c) absorption and (b) reduced scattering
coefficients in the high absorption regime. Each point in (a) and (c) is associated with
a different scattering value whereas each point in (c) and (d) is associated to a different
absorption value.
3.2.2. High absorption tissue phantoms
For high absorption phantom experiments, reconstructions were based on a reference phantom
with µa = 0.66 mm−1 and µs ′ = 1.1 mm−1. The results are shown in Fig. 3(c, d). Average errors
of 5.2% and 4.4% were obtained for absorption and reduced scattering, respectively. The average
standard deviations were 5.2% and 5.0% for absorption and reduced scattering.
3.2.3. Profilometry
Implementation and validation of the profilometry correction algorithm to SFDI optical properties
was done for both phantom shapes: staircase and quarter-sphere. Fig. 4(a, b) shows the SFDI-
computed absorption and reduced scattering coefficients, respectively, on each step of the staircase
with and without the geometric correction applied. The geometric correction allowed to reduce
the average error on all steps due to height variations from 127% to 3.3% for absorption and
from 28% to 2.5% for reduced scattering. Fig. 4(c, d) shows µa and µs ′ over all considered θ
intervals on the quarter-sphere phantom with and without the geometric correction. The average
error for all angles was reduced from 15.0% to 4.7% for absorption and from 5.8% to 2.9% for
reduced scattering.
3.3. Fluorescence and reflectance spectroscopy
The attenuation-corrected fluorescence (CF), as well as the uncorrected fluorescence (Fraw) from
the PpIX emission peak at 635 nm are shown in Fig. 5 as a function of the real fluorophore
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Fig. 4. (a) Absorption and (b) reduced scattering coefficients averages on staircase steps with
and without the geometric correction. (c) Absorption and (d) reduced scattering coefficients
averages computed on sections (∆θ = 5°) of the quarter-sphere centered at an azimuthal
angle θ with and without the geometric correction.
concentration (CPpIX) in the phantoms. Figure 5(a) shows raw fluorescence measurements for
all µa and µs ′ values evidencing almost no linear trend (correlation) with the theoretical PpIX
concentration (R2 = 0.42). This is because, for a given concentration of PpIX, different variations
in absorption and scattering affect the level of detected light and can be misconstrued as variations
in fluorophore concentration. However, Fig. 5(b) shows that using the CF model improved the
correlation between real concentration and detected signals to R2 = 0.83 from R2 = 0.42 in the
case of raw fluorescence.
Fig. 5. Measured PpIX emission peak intensity as a function of the real PpIX concentration
in liquid optical phantoms: (a) raw fluorescence and (b) attenuation-corrected fluorescence.
Each phantom is represented by a point with a different color, each corresponding to a
different value of absorption and reduced scattering coefficient.
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3.4. Ex vivo human prostate imaging
Figure 6 shows images of the prostate specimen slice for all optical modalities, including
the absorption coefficient, the reduced scattering coefficient as well as the area under curve
(AUC) -sum over all wavelengths- from reflectance, raw fluorescence and attenuation-corrected
fluorescence (CF) spectra. The geometric correction from profilometry was applied to the SFDI
optical properties maps. Reconstructed height variations of approximately 1 mm amplitude
causing artificial striped patterns visible in the 3-D profile could be explained by stochastic
noise causing inaccuracies in phase demodulation. Based on the results presented in section
3.2.3, erroneous variations of 1 mm height will introduce an error of approximately 5% in
absorption and 2% in scattering coefficient maps; these numbers are comparable to the standard
deviation obtained in flat phantoms (section 3.2.2). Thus, the impact of these noise-induced
height artefacts should not exceed the expected variance in SFDI reconstruction. Overall, the
effect of the profilometry correction on the µa and µs ′ profiles of the prostate was limited.
Fig. 6. Photograph (top right) and optical images of a prostate specimen slice in terms of
the absorption coefficient, the reduced scattering coefficient and the integral under the curve
of reflectance, raw fluorescence, and attenuation-corrected fluorescence (CF) spectra.
Figure 7 shows average reflectance, fluorescence and CF spectra for each of the 6 biologically
distinct regions identified by the pathologist while Table 1 presents the average values and
standard deviation for absorption, scattering, and CF spectrum AUC for these regions. The
average SNR (over each region) per detection band for the reflectance signal is also reported
to highlight potential decreases in signal quality in certain prostate regions. The SNR was
computed as the square root of total detected light intensity assuming all measurements were shot
noise (photonic noise) dominated. Figure 8 shows the boxplots associated with average SNR,
absorption and reduced scattering coefficients as well as CF spectrum AUC. A Kruskal-Wallis
test combined with pairwise comparisons demonstrated that, for all three sources of optical
contrast, every region showed statistically significant differences from one another (p< 0.01).
When conducting these statistical tests with Fraw instead of CF, p< 0.01 was also obtained. To
highlight the impact of the geometric correction, Table S1 (Supplemental materials) shows
the average values and standard deviation for absorption, scattering, and CF with and without
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the profilometry correction. The statistical tests also led to p< 0.01 without the profilometry
correction.
Fig. 7. (a) Photograph of the prostate specimen with biologically-distinct regions identified
by a pathologist: 1) anterior stroma, 2) urethra, 3) hyperplasia, 4) ejaculatory ducts, 5)
peri-prostatic, 6) peripheral zone. Average spectra computed for each region of interest.
(b) Attenuation-corrected fluorescence (CF), (c) reflectance and (d) raw fluorescence. The
colors of the contour delineations in (a) match the colors of their associated spectra in (b),
(c) and (d).
Fig. 8. Boxplots comparing (a) the SNR per spectral band, (b) the attenuation-corrected
fluorescence (CF), (c) the absorption coefficient and (d) the reduced scattering coefficient of
all prostate regions: 1) anterior stroma, 2) urethra, 3) hyperplasia, 4) ejaculatory ducts, 5)
peri-prostatic, 6) peripheral zone. Outliers are represented by red crosses.
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Table 1. Average and standard deviation of the optical biomarkers for each region of the prostate
specimen interrogated with the imaging system, including the number of image pixels over which
they were computed and the signal-to-noise ratio (SNR) per spectral band.
Prostate region # of pixels Average SNR/band CF [a.u.] µa [mm−1] µs′ [mm−1]
Anterior stroma (1) 14432 207± 13 15.2± 2.4 0.30± 0.06 2.09± 0.24
Urethra (2) 1938 141± 35 32.6± 10.3 0.74± 0.09 1.23± 0.53
Hyperplasia (3) 28942 112± 8 9.7± 2.1 0.43± 0.07 1.44± 0.19
Ejaculatory ducts (4) 1498 149± 15 31.1± 5.0 0.66± 0.08 1.60± 0.38
Peri-prostatic (5) 9203 112± 31 53.1± 27.3 1.22± 0.31 1.88± 1.03
Peripheral zone (6) 19813 237± 28 40.9± 11.3 0.52± 0.10 2.43± 0.46
The data was further divided into prostatic (regions 1,3,6) and extra-prostatic tissue (regions
2,4,5) categories. Figure 9 shows the corresponding boxplots associated with average SNR,
absorption and reduced scattering coefficient as well as CF. A Kruskal-Wallis test demonstrated
that, for all three sources of optical contrast, prostatic and extra-prostatic tissue showed statistically
significant differences from one another (p< 0.01). These statistical tests were also conducted
and led to p< 0.01 without the profilometry correction and with Fraw instead of CF.
Fig. 9. Boxplots comparing (a) the SNR per spectral band, (b) the attenuation-corrected
fluorescence (CF), (c) the absorption coefficient and (d) the reduced scattering coefficient
between prostatic and extra-prostatic regions of the specimen. Outliers are represented as by
red crosses.
4. Discussion and conclusions
This study presented the development and tissue phantoms validation of a multimodal wide-field
imaging system as well as initial proof-of-concept ex vivo measurements in human prostate. This
demonstrated new quantitative tissue biomarkers that could potentially distinguish biologically
distinct regions, including prostatic vs. extra-prostatic structures. It is the first step in a larger-scale
project aiming to automate tissue characterization during radical prostatectomy procedures to
limit the risk of tissue damage and eventually assess whether optical spectroscopy can detect
cancer that has invaded beyond the confines of the prostate organ.
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In the SFDI-based reconstruction of absorption and reduced scattering that was reported here,
the average errors across both low and high absorption phantom experiments were similar to other
studies [54,57,76–79]. However, there was a small increase in reconstruction error (+0.5%) for
reduced scattering in the high absorption phantom set when compared to the low absorption set.
It should be noted that part of the observed errors could be explained by inherent uncertainties
associated with the properties used as theoretical values for the optical phantoms. For phantoms
with µa= 0.17 mm−1 to µa= 0.44 mm−1, reconstructions based on a reference phantom with
µa = 0.05 mm−1 led to increased errors (0.4% for µa, 1.6% for µs ′) when compared with the
average errors computed over the whole phantoms set. When choosing a reference phantom
with optical properties closer to the properties targeted for reconstruction (µa= 0.3 mm−1, µs ′ = 1
mm−1), reconstruction errors decreased by 1% when compared to the errors computed from
the whole phantom set. This phenomenon was also observed in other work and highlights the
importance of choosing a reference with optical properties as close as possible to the interrogated
tissue associated with the biological application of interest [57]. Despite the reported decreases
in performance for the high absorption phantom experiments, the reference phantom used for that
dataset led to acceptable system performance across a range of absorption and reduced scattering
coefficients representative of prostate samples.
The profilometry technique reduced the average error in absorption and elastic scattering by
124% and 25.5% respectively for a staircase phantom of 24 mm height. The reported errors
of 3.3% and 2.5% for µa and µs ′ (after correction) were within the error margins of 5.8% and
2.9% for the reconstruction of the same optical properties in high absorption flat liquid phantoms.
The increased size of the error bars in absorption and scattering (after the height correction was
applied) were mainly caused by reconstructed height variations within each stair and could be a
consequence of bubbles on the surface of the PDMS phantom.
For the sphere quadrant, in regions with the azimuthal angle θ ≤ 50° the errors were reduced
by 10.3% and 2.9% for µa and µs ′, respectively. The resulting errors of 4.7% and 2.9% (after
correction) were within the expected 5.8% and 2.9% errors for the flat liquid phantoms with the
same optical properties. However, the size of the error bars was unchanged after the correction
possibly due to stochastic noise (less signal-to-noise ratio in high azimuthal angle regions)
causing SFDI phase demodulation artefacts. To remove these artefacts, and potentially increase
the azimuthal angle covered by the reconstruction, a different profilometry technique using higher
spatial frequencies could be explored, although with these techniques obtaining absolute height
values requires more involved calibration methods that may limit practical use during surgery
[62,80]. The phantom results validate the efficiency of the 3-D profile to partially correct optical
properties for geometrical features associated with height variations within the depth of field
of the system if the curvature variations are associated with normal surface vector azimuthal
angles <50°. An overall decrease in accuracy of reconstructed optical properties and reduced
effectiveness of the geometric correction is expected for high curvature changes such as sharp
depressions in the imaged specimens. This is for example the case for the central depression
(urethra) in the imaged prostate specimen where the SFDI results could simply be excluded from
further analyses.
In the fluorescent phantom studies, the calibration procedure and the attenuation correction
model were able to correct for the instrument response function. The attenuation correction
also reduced the impact of non-fluorescence attenuation factors despite the relatively larger
spread in absorption and reduced scattering coefficients considered when compared to other
PpIX quantification studies found in the literature [55,63,75,81]. The CF method significantly
improved the correlation between theoretical PpIX concentration and the fluorescence intensity
measurements from R2 = 0.42 for raw fluorescence to R2 = 0.83 for attenuation-corrected
fluorescence.
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However, it was observed that fluorescence measurements from the lowest absorption phantom
(µa = 0.05 mm−1, µs ′ = 0.75 mm−1) and the highest PpIX concentration was overcorrected by
the CF method. In fluorescent phantoms the total absorption (µa,tot) is the sum of chromophore
absorption (µa from the food coloring dye) and fluorophore absorption (µaf from PpIX), which is
proportional to the concentration of the fluorescent molecule. Often in tissue µa,tot ≈ µa since
µa >> µa,f , but for this low absorption phantom µa,f can no longer be neglected which is in
breach of one of the validity conditions for Eq. (1). For this phantom, SFDI measurements lead
to an absorption coefficient effectively larger than 0.05 mm−1, which in turn leads to a lower
CF intensity. However, this is not expected to be an issue for prostate measurements where
fluorophore concentrations are low and lead to an effective absorption much smaller compared
the absorption from chromophores [33,42,51].
A limitation of the CF method is that it does not account for the varying sampling depth
associated with different emission wavelengths. As a result, CF values should be interpreted with
the understanding that the CF spectrum AUC represents an effective fluorescence measurement
averaged over depths sampled across the spectral detection range. Another potential limitation
of the approach is that the attenuation correction may not be able to disentangle fluorescence
from absorption and scattering with sufficiently high precision to detect subtle tissue biochemical
modifications, including local pH changes. Using the sample average values µa = 0.52 mm−1
and µs ′ = 1.71 mm−1, an estimation of imaging sampling depth could be obtained at 435 nm
with a Monte-Carlo light transport modeling technique using as input parameters the average
profile-corrected SFDI-computed optical properties of the prostate [82]. The resulting prediction
is that 75% of the detected light came from the first 513 µm tissue layer, which corresponds to an
average over all measured spatial frequencies.
The optical properties maps for the prostate specimen showed distinct features for absorption
and reduced scattering, evidencing both phenomena were reconstructed with minimal optical
contrast crosstalk. However, applying the profilometry-based geometric correction led only to
minor changes in the optical properties maps, which is likely indicating that the height and
curvature changes of the prostate specimen are too small to have a significant impact on the
results. Overall, absorption values were high in the prostate and on average they were of the
same order as reduced scattering, justifying the use of a high absorption reference phantom in
SFDI reconstructions. There were important variations in optical properties within the imaged
specimen, potentially resulting in uneven accuracies in optical properties reconstruction across
the imaging field. This is because SFDI reconstruction accuracy decreases when the difference
between absorption/scattering values of the imaged sample and those of the reference phantom
increases. However, prostate optical properties values could not be found in literature at 435 nm
for comparison; most studies measured absorption and scattering in the 600-1000 nm range [73].
Fluorescence and reflectance spectroscopy signals are not entirely uncorrelated, there were
image features seen in the SFDI images that could also be seen in the spectroscopy images. As an
example, the anterior stroma, which is characterized by a low absorption coefficient, also featured
high reflectance and fluorescence. After applying the geometric correction and the fluorescence
correction model, the resulting CF image was not visibly dependent on the SFDI-derived maps
or any other geometrical features. The only still noticeable feature was the urethra geometric
depression, representing only a small fraction of the sample. The fluorescence spectra acquired
at each point in the image presented a similar shape to that of other studies for prostate tissue and
other biological tissue excited at similar wavelengths [83,84]. However, the reflectance spectra
did not present hemoglobin features, likely because the prostate measurements were made ex
vivo. No studies imaging similar prostate specimens were found for comparison.
Statistical analyses of the prostate specimen images revealed that all pairwise comparisons
between different regions had p-values indicative of significant differences for absorption, reduced
scattering, and CF AUC. Note that while the dimensional reduction of CF simplifies results
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analysis it also reduces the informational content of the biomarker since several features on
the spectrum could be used as features for differentiation. In the boxplots, the median can
highlight absolute value differences in optical properties between regions, the IQR can be used
as a surrogate for tissue heterogeneity and the maximum, minimum and number of outliers
can be indicators of extreme variations in data that may have a biological origin but could also
be attributable to low levels of SNR or artefacts due to the geometric correction not being
able to fully account for tissue curvature changes. Most regions had noticeable differences in
median values for all modalities. Although there were some exceptions, such as the urethra
and ejaculatory ducts in CF, these differed significantly in IQR and maximum-minimum values.
Peri-prostatic tissue tended to have higher variability but was also the region with the lowest SNR
in reflectance signal, potentially explaining this observation. In general, CF had a smaller IQR
compared to the other sources of optical contrast but it had the highest number of outliers. This
could be traced back to the noise amplification due to mathematical operations (divisions and
multiplications) required to apply the CF model. On the other end, absorption had more marked
differences in median and IQR between regions than other modalities, implying chromophore
concentrations varied importantly. It was also noted that µs ′ values had the highest heterogeneity
for all regions. However, there was a significant variation in SNR between the regions, with
several medians and IQR that prevented a straightforward visible interpretation of the results
when comparing individual regions.
When comparing prostatic and extra-prostatic tissue, the p-values indicated that all modalities
showed potential for differentiation. However, since the p-values were all p< 0.01 a direct
comparison of the differentiation potential of the modalities could not be made. The low sample
number also prevented a satisfactory analysis of the impact of the attenuation and profilometry
corrections on classification, as initial tests showed Fraw and the optical properties without
geometrical correction also attained p< 0.01. The difference in median was small for CF, but
prostatic tissue presented a different Q1-Q2-Q3 distribution, had a smaller maximum-minimum
range and fewer outliers. Absorption had significant median differences and values did not
overlap in IQR. Reduced scattering presented a difference in medians and IQR. Furthermore, the
SNR was very similar between the two categories, meaning differences between tissue categories
were likely not due to noise-induced variability.
Further developments will be required to ensure utility of the multimodal imaging technique in
a clinical/surgical setting. The current acquisition time for prostate specimen imaging was ∼15
minutes which is unsuitable for surgical applications where information needs to be provided
rapidly. However, a system redesign could decrease imaging time by at least 2 orders of magnitude
by increasing illumination power, which is currently much lower than ANSI safety standards,
and/or by replacing the LCTF (<10% transmission at lower visible wavelengths) with more
effective filtering elements (e.g. interference filters). Another limitation of the system was that
the profilometry technique and the geometric correction to SFDI-based reconstructions were
only partially able to account for specimen height and curvature variations. In future system
developments, this could be remedied either by considering a more accurate reconstruction
technique using not only low frequency shifted patterns but also (in combination) high frequency
patterns. Another solution could be envisioned where imaging is achieved with an imaging
probe system making direct contact with the tissue. This would allow the surface to be rendered
flat prior to imaging and, to a large extent, eliminate issues with specular reflections through
index-matching between the tissue and a front-viewing imaging window.
The specimen imaging results preliminarily demonstrate the system’s capacity to differentiate
biologically distinct prostate regions. However, those findings were only based on one prostate
implying no definite conclusions can be reached. A clinical study is being conducted involving
a large number of radical prostatectomy patients where the goal is to quantitatively evaluate
the potential of the optical biomarkers to differentiate biologically distinct normal/benign tissue
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regions but to also achieve cancer detection. To this end detailed dimensional reduction techniques
(e.g. principal components analysis) will be used to determine the features most contributing to
the variance of interest (i.e. extra prostatic vs. prostatic tissue, normal/benign vs. cancer) and
machine learning models will be produced, validated and tested ensuring generalization to new
data for live use during surgical procedures.
Future work will also tackle challenges relating with the presence of blood in the surgical
cavity, which can dramatically attenuate optical signals and potentially make measurements,
especially the absorption coefficient, non-specific to the tissue of interest. These effects could
be partially addressed through a combination of surgeon training –to image only when blood
pooling is minimal– and decrease in imaging time. This could be facilitated by the addition of
another optical method for example intraoperative video-rate hemodynamic response assessment
using a time-frequency associated with breathing to discriminate between blood pooling and
blood vessels.
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